INGN 225 / Lumos Pharma - LARVOL DELTA

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - P2 | N=14 | Terminated | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2023 ➔ May 2022 | Active, not recruiting ➔ Terminated; Sponsor closed study

Trial completion date • Trial termination • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • TP53

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - P2 | N=14 | Active, not recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Apr 2022 ➔ Dec 2022

Trial primary completion date • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • IFNG • TP53

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - P2; N=14; Active, not recruiting; Sponsor: H. Lee Moffitt Cancer Center and Research Institute; Trial primary completion date: Dec 2021 ➔ Apr 2022

Clinical • Trial primary completion date • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • IFNG • TP53

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - P2; N=14; Active, not recruiting; Sponsor: H. Lee Moffitt Cancer Center and Research Institute; Trial completion date: Apr 2024 ➔ Dec 2023; Trial primary completion date: Apr 2022 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • IFNG • TP53

To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid (clinicaltrials.gov) - P2; N=69; Completed; Sponsor: H. Lee Moffitt Cancer Center and Research Institute; Active, not recruiting ➔ Completed; Trial completion date: Dec 2019 ➔ Jan 2019

Clinical • Combination therapy • Trial completion • Trial completion date